InvestorsObserver
×
News Home

Is MEI Pharma Inc (MEIP) a Stock to Watch After Gaining 11.96% This Week?

Thursday, October 07, 2021 12:57 PM | InvestorsObserver Analysts

Mentioned in this article

Is MEI Pharma Inc (MEIP) a Stock to Watch After Gaining 11.96% This Week?

The market has been high on MEI Pharma Inc (MEIP) stock recently. MEIP gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
MEI Pharma Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on MEIP!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With MEIP Stock Today?

MEI Pharma Inc (MEIP) stock is trading at $3.09 as of 12:45 PM on Thursday, Oct 7, an increase of $0.15, or 5.29% from the previous closing price of $2.93. The stock has traded between $2.92 and $3.15 so far today. Volume today is above average. So far 1,461,350 shares have traded compared to average volume of 421,507 shares. To screen for more stocks like MEI Pharma Inc click here.

More About MEI Pharma Inc

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer. Geographically, all the business activities function through the region of the United States. Click Here to get the full Stock Report for MEI Pharma Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App